Given the potential of gene therapies in targeting the underlying cause of a disease at cellular level, the gene therapy market has increased considerably over the past few years. Currently, more than 285 gene therapies are being evaluated in different phases of clinical development. Further, various gene therapy developers have raised more than USD 10 billion capital during the year 2021. With the growing interest in such therapies, the demand for novel gene delivery vectors has also increased. Among various gene delivery vectors available, adeno-associated viral vectors (AAV vectors) have emerged as one of the most efficient viral vectors. Till now, the USFDA has approved two adeno-associated viral vectors based drugs, LUXTURNA® and ZOLGENSMA®.
In order to cater to the demand, close to 100 players, across the globe, have emerged for the development and manufacturing of adeno-associated viral vectors. In fact, a number of these companies also offer advanced technology platforms, enabling the processing of AAV vectors and related therapies across different scales of operation. Various industry and non-industry players are actively engaged in research and development of novel gene delivery technologies, which are safe and effective.
155+ Clinical Trials have been / are being conducted
The stakeholders have invested extensively in conducting clinical trials for evaluating the efficacy of the therapeutic candidates delivered using novel AAV vectors in the treatment of a variety of indications
~4,300 Patent Filed / Granted related to Adeno-associated viral vectors
Examples of leading industry stakeholders, in terms of most patent applications filed include Genzyme, Voyager Therapeutics, REGENXBIO, Baxalta and Spark Therapeutics
200+ Partnerships and Collaborations signed in the AA Viral Vectors Domain
The growing partnerships and collaborations signed between different stakeholders is indicative of the significant demand of gene delivery systems and related therapies from the past few years
As projected by Roots Analysis, oncological disorders therapeutic area will have majority share in the AAV vectors market
As projected by Roots Analysis, the overall Adeno-Associated Viral Vectors market is projected to grow from USD 1.9 billion in 2022 to USD 11.1 billion by 2035, exhibiting a CAGR of 14% during the forecast period.
You can also download the SAMPLE REPORT on adeno-associated viral vectors by Roots Analysis.